V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004826 | 310002162 | 1.58 | 61.3 | Adjuvant (A) | null | 2016-01-08 | MEDROXYPROGESTERONE | N | null | 310024044 | DABRAFENIB |
| 310004827 | 310002163 | 0 | 62 | Adjuvant (A) | 2016-06-02 | 2016-06-02 | Bortezomib + MELPHALAN | N | Y | 310024046 | ICON8B TRIAL |
| 310004828 | 310002163 | 1.76 | 62.9 | Curative (C) | 2016-03-16 | 2016-04-05 | DABRAFENIB | N | N | 310024046 | CAPECITABINE + CISPLATIN + RT |
| 310004829 | 310002163 | 1.58 | 53.8 | Adjuvant (A) | 2016-10-28 | 2016-10-28 | Sunitinib | N | N | 310024046 | AC |
| 310004830 | 310002163 | 1.62 | null | null | 2014-09-28 | 2014-09-28 | Enzalutamide | Y | Y | 310024046 | ECF |
| 310004831 | 310002164 | 1.55 | 63.9 | Curative (C) | 2016-11-08 | 2016-11-16 | Trastuzumab Subcutaneous | N | N | 310024082 | BEVACIZUMAB |
| 310004832 | 310002165 | 1.71 | null | null | 2015-03-19 | 2015-03-30 | DABRAFENIB | N | N | 310024094 | CISPLATIN + TOPOTECAN |
| 310004833 | 310002166 | 1.73 | 112 | Not known (9) | 2014-10-05 | 2014-10-06 | Carboplatin + Vinorelbine Oral | N | null | 310024103 | CISPLATIN + FLUOROURACIL + RT |
| 310004834 | 310002167 | 1.71 | 54.2 | Disease modification (D) | 2013-10-24 | 2013-11-08 | Cyclophosphamide Fludarabine (Oral) | N | N | 310024105 | FEC |
| 310004835 | 310002168 | 1.63 | 51 | null | 2016-08-12 | 2016-09-10 | Gemcitabine + Capecitabine | N | Y | 310024111 | DABRAFENIB |
| 310004836 | 310002168 | 1.47 | 76 | Palliative (P) | 2015-04-30 | 2015-05-16 | DABRAFENIB + TRAMETINIB | 02 | N | 310024111 | MITOXANTRONE |
| 310004837 | 310002169 | 0 | null | Palliative (P) | 2016-10-14 | 2016-10-17 | Docetaxel | N | N | 310024121 | SUNITINIB |
| 310004838 | 310002169 | 1.69 | 82.3 | Curative (C) | 2017-01-17 | 2017-01-18 | DA-EPOCH-R | N | N | 310024121 | ALEMTUZUMAB |
| 310004839 | 310002169 | 1.78 | 68 | Curative (C) | null | 2015-06-09 | DABRAFENIB | N | N | 310024121 | CLADRIBINE |
| 310004840 | 310010429 | null | 100.2 | Palliative (P) | 2014-11-22 | 2014-11-25 | Nilotinib | N | N | 310024130 | METHOTREXATE HIGH DOSE |
| 310004841 | 310002170 | 1.7 | 0 | Disease modification (D) | 2013-09-12 | 2013-09-14 | CAPECITABINE + CARBOPLATIN | 02 | N | 310024135 | IRINOTECAN + TEMOZOLOMIDE |
| 310004842 | 310002171 | 1.82 | 69 | Palliative (P) | 2017-06-04 | 2017-07-03 | RCEOP | N | Y | 310024137 | POUT TRIAL |
| 310004843 | 310006913 | 1.64 | 62 | Palliative (P) | 2015-09-24 | 2015-10-05 | CVP R | 02 | Y | 310024138 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 310004845 | 310002173 | null | 85.3 | null | 2017-03-28 | 2017-03-28 | IBRUTINIB | 02 | null | 310024150 | SELPAC TRIAL |
| 310004846 | 310002174 | 1.77 | null | Palliative (P) | null | 2016-06-26 | MITOMYCIN | 02 | null | 310024160 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE |
| 310004847 | 310002175 | null | 71.3 | Curative (C) | 2012-12-16 | 2013-03-01 | BEP 5 Day | 02 | Y | 310024172 | CAP + RT |
| 310004848 | 310002176 | 1.68 | 60.8 | Curative (C) | 2014-12-12 | 2014-12-13 | Cisplatin + Etoposide + RT | 01 | N | 310024173 | CAPECITABINE + MITOMYCIN + RT |
| 310004849 | 310002176 | 1.79 | 62.4 | null | 2015-04-26 | 2015-05-07 | Irinotecan + Modified De Gramont | 02 | null | 310024173 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 310004850 | 310009225 | 1.69 | 73.9 | Curative (C) | 2014-04-26 | 2014-04-26 | CYCLO + RITUXIMAB + VINCRISTINE | 2 | N | 310024177 | ETOPOSIDE + IFOSFAMIDE |
| 310004851 | 310002177 | 1.64 | 94.05 | Disease modification (D) | 2015-12-25 | 2017-01-01 | Carboplatin + Vinorelbine Oral | 02 | N | 310024179 | METHOTREXATE HIGH DOSE |
| 310004852 | 310002178 | 1.67 | 71.7 | Neo-adjuvant (N) | 2014-01-28 | 2014-01-28 | Doxorubicin + Ifosfamide | N | N | 310024182 | IVE |
| 310004853 | 310002179 | 1.82 | 88.4 | Adjuvant (A) | 2014-05-29 | 2014-06-01 | Cytarabine HD + Methotrexate HD | 02 | N | 310024193 | R CODOX M |
| 310004854 | 310002180 | null | 38.8 | null | 2016-04-26 | 2016-04-29 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE | null | N | 310024200 | ETOPOSIDE |
| 310004855 | 310002181 | 1.68 | null | Disease modification (D) | 2013-01-29 | 2014-11-12 | CARBO + ETOPOSIDE + VINCRISTINE | 02 | N | 310024215 | CVP |
| 310004856 | 310002181 | 1.6 | 55 | Curative (C) | 2015-03-04 | 2015-03-19 | PMitCEBO | 2 | N | 310024215 | DOCETAXEL + GEMCITABINE |
| 310004857 | 310002181 | 1.54 | 66.3 | Curative (C) | 2015-12-17 | 2015-12-31 | ALL UKALL2011 TRIAL | 02 | N | 310024215 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310004858 | 310002182 | null | 82 | Palliative (P) | 2014-04-26 | 2014-05-09 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 310024235 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310004859 | 310002183 | null | 49.2 | null | 2017-05-30 | 2017-06-02 | Bevacizumab | N | N | 310024238 | BEVACIZUMAB + TEMOZOLOMIDE |
| 310004860 | 310002184 | 2.01 | 61 | Neo-adjuvant (N) | 2016-07-26 | 2018-01-03 | BEAM | null | N | 310024239 | IVE |
| 310004861 | 310002185 | 1.53 | null | Palliative (P) | 2014-11-02 | 2014-11-02 | CVP R | 02 | null | 310024241 | CLADRIBINE |
| 310004862 | 310002186 | 1.85 | 90.3 | Palliative (P) | 2019-03-12 | 2019-03-15 | CARBOPLATIN + FLUOROURACIL | N | N | 310024243 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 310004863 | 310002186 | 1.61 | 67.6 | Adjuvant (A) | 2017-11-17 | 2017-11-25 | CAPECITABINE + TEMOZOLOMIDE | N | N | 310024243 | PAZOPANIB |
| 310004864 | 310002187 | 1.65 | 84.2 | Neo-adjuvant (N) | 2014-06-10 | 2014-06-10 | FEC 100 | N | N | 310024262 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310004865 | 310002188 | 1.74 | -1 | Curative (C) | 2014-02-18 | 2014-03-12 | Chlorambucil | null | N | 310024265 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 310004866 | 310002189 | 1.69 | 64.4 | Palliative (P) | 2014-11-30 | 2014-12-06 | Sunitinib | N | N | 310024271 | VINBLASTINE |
| 310004867 | 310002190 | 1.69 | 95 | Neo-adjuvant (N) | 2015-03-09 | 2015-03-22 | CETUXIMAB | 02 | N | 310024277 | CARBOPLATIN + PEMETREXED |
| 310004868 | 310002191 | 0 | 81 | Adjuvant (A) | 2016-06-03 | 2016-06-09 | Abiraterone | N | N | 310024278 | CARBOPLATIN + RT |
| 310004869 | 310002192 | 1.65 | 72 | Palliative (P) | 2013-06-17 | 2013-07-05 | Cyclophosphamide + Etoposide (PO) | 02 | N | 310024290 | CARBO + FLUOROURACIL |
| 310004870 | 310002193 | 0 | null | Palliative (P) | 2014-01-24 | 2014-01-28 | DABRAFENIB + TRAMETINIB | N | N | 310024315 | ALEMTUZUMAB |
| 310004871 | 310006917 | 0 | 121.9 | Disease modification (D) | 2016-06-08 | 2016-06-14 | Capecitabine 35days + RT | 02 | N | 310024318 | CISPLATIN + VINORELBINE |
| 310004872 | 310006917 | 1.62 | null | Palliative (P) | 2016-04-04 | 2016-04-11 | Cisplatin + Pemetrexed | N | N | 310024318 | CARBO + ETOPOSIDE + VINCRISTINE |
| 310004873 | 310010430 | 0 | 64 | Curative (C) | 2015-02-06 | 2015-02-06 | SelPac Trial | N | N | 310024334 | FEC |
| 310004874 | 310010430 | 1.65 | 64 | null | 2013-07-17 | 2013-07-25 | ICON8B TRIAL | 02 | N | 310024334 | ICON8B TRIAL |
| 310004875 | 310010430 | 1.76 | 111.8 | Adjuvant (A) | 2017-03-18 | 2017-04-28 | CETUXIMAB | 2 | N | 310024334 | FLUOROURACIL + RT |
| 310004876 | 310010430 | 0 | null | Adjuvant (A) | 2013-10-04 | 2013-10-08 | Enzalutamide | N | N | 310024334 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |